Pioneering oral treatment greenlit for myeloma patients

A ground-breaking oral treatment that could increase survival by 10 months has been given the green light for patients with incurable blood cancer in England and Wales.

The National Institute for Health and Care Excellence (NICE) has approved the use of ixazomib (Ninlaro®) in combination with lenalidomide (Revlimid®) and dexamethasone (IRD) – the first oral triplet treatment for myeloma.

IRD is aimed at patients whose cancer has returned for a second or third time and has been shown to increase average survival by 10 months.

The treatment has also been shown to increase remission times by nine months on average.

Unlike standard myeloma treatments, this game-changing new drug combination can be taken at home, saving vulnerable patients from exhausting and, in the wake of the cost-of-living crisis, potentially expensive weekly trips to the hospital for treatment.

Around 1,000 patients could benefit from this at-home treatment each year.

Shelagh McKinlay, Myeloma UK’s Director of Research and Advocacy, said:

“IRD is a game-changer and we’re absolutely delighted with NICE’s decision. We know that over time people become resistant to specific drugs, so it is absolutely crucial to constantly develop new treatment options and to add yet more weapons to patients’ armoury.

As the first oral triplet treatment for myeloma, IRD is truly paving the way for more patient-friendly treatments.

Not only does it increase average survival by 10 months and extend remission by an average of nine months, but it gives patients something they could only have dreamed of just a few years ago: a life that doesn’t revolve around weekly hospital appointments. And as the cost-of-living crisis bites, the heavy financial burden of constantly travelling to and from the hospital can’t be underestimated.

But while patients in some parts of the country now benefit from a treatment that could make a marked difference to their day-to-day lives, others in Scotland have no such luck. Healthcare should not come down to a postcode lottery and we won’t rest until everyone has access to the latest, most effective and patient-friendly treatments – no matter where they live in the UK.”

Ixazomib is a proteasome-inhibitor drug. It works by blocking proteasomes – large molecules found in all cells of the body – from breaking down unwanted proteins. Myeloma cells rely more heavily on proteasomes, as they produce more proteins than normal healthy cells. They are therefore much more sensitive to ixazomib.

The triplet treatment was initially rolled out in 2017 through the Cancer Drugs Fund – a pot of money which provides cancer patients in England with faster access to the most promising new drugs pending full approval from NICE.

Over time, IRD has become the standard for patients on their third or fourth round of treatment.

John Ellwood, a retired headteacher from West Oxfordshire, was among the first patients to receive IRD when his cancer returned for the third time. He has been in remission ever since.

John was just 58 when, in 2011, he was diagnosed with MGUS, a benign condition which had just a one per cent chance of developing into a cancer like myeloma. A year later, he was told the condition had progressed to myeloma.

John told us:

“I am so glad ixazomib in combination with lenalidomide and dexamethasone has been approved by NICE. To be able to take an effective drug with minimal side-effects at home as part of your treatment is hugely beneficial – no weekly trips to the hospital, no car parking hassles, no long hours attached to a drip! This makes a significant psychological as well as a physical contribution to the treatment of myeloma. I’m pretty much living a normal life now.”

At the peak of the pandemic, the handy at-home treatment was made available to patients much earlier in their treatment journey to help reduce hospital appointments as much as possible.

Prof Graham Jackson, consultant haematologist at Newcastle Hospitals NHS Foundation Trust and professor of clinical haematology at Newcastle University, said:

“It is fantastic news for myeloma patients that NICE have approved IRD therapy. This is an important triplet therapy giving an average of nine months longer in remission and effective in both low- and higher-risk disease. “It is the only triplet therapy that is all oral meaning patients have to spend less time in hospital receiving treatment. This regime has been widely used through the Cancer Drugs Fund and has been extensively used during the COVID-19 pandemic as NHS England recognised the value to both the NHS and the patient of an effective oral therapy for myeloma patients.”

What is the Cancer Drugs Fund?

The Cancer Drugs Fund (CDF) is a pot of money which provides cancer patients in England with faster access to the most promising new drugs. The CDF only applies to England. However, Wales has a New Treatments Fund which also aims to speed up access to the latest drugs, but which is not exclusively aimed at cancer. In Scotland there is the New Medicines Fund for people with rare or incurable conditions, including cancer. Unfortunately, no such dedicated fund exists in Northern Ireland.

What is the CDF trying to achieve?

The CDF aims to make promising cancer drugs available to patients before they are fully approved for use on the NHS by the National institute for Health and Care Excellence (NICE). It has three key objectives:

  • Provide patients with faster access to the most promising new cancer drugs.
  • Help ensure more value for money for taxpayers.
  • Offer pharmaceutical companies who price their drugs responsibly a new fast-track route to NHS funding.

The CDF can be thought of as part of the NICE process for reviewing cancer drugs, providing NICE with a third option when appraising cancer drugs.

NICE can say:

  • Yes – the drug should be routinely available on the NHS.
  • No – the drug should not be routinely available on the NHS.
  • Maybe – the drug is recommended for use within the CDF for a set time period while more evidence on the drug is collected.

NICE will use the CDF route if it thinks that a drug shows promise but there isn’t enough evidence for a straight ‘yes’ decision. When taking this ‘maybe’ route through the CDF, NICE will look again at the drug, usually after two years or so, to consider the additional evidence that has been collected before making a final yes or no decision.

What has the CDF done for myeloma?

Ixazomib (Ninlaro®) in combination with lenalidomide (Revlimid®) and dexamethasone was approved by the CDF in December 2017.

In 2018, daratumumab monotherapy became the second myeloma treatment to be approved via the CDF.

Close-up photograph of a hand holding a mobile phone.

Stay in touch

We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.